Products for Research Use Only

FHT-1015

CAT: 0804-HY-144896-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-144896-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
FHT-1015 is a selective SMARCA4 (IC50 = 4 nM) and SMARCA2 (IC50 = 5 nM) (also known as BRG1 and BRM) inhibitor. FH-1015 is an allosteric inhibitor that causes conformation change in the BRG1/BRM protein upon interaction with an allosteric site, inhibiting ATPase activity. FH-1015 interferes with tumor cell growth and migration. FH-1015 can be studied in research for uveal melanoma and hematologic cancer[1][2][3][4].
CAS Number
2368903-18-6
UNSPSC
12352005
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/fht-1015.html
Purity
98.41
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(C1=CN(C=C1)S(C)(=O)=O)N[C@@H](CCSC)C(NC2=NC(C3=CC(C4=CC=NC=C4)=CC=C3)=CS2)=O
Molecular Formula
C25H25N5O4S3
Molecular Weight
555.69
References & Citations
[1]Seedor, R. et al., (2021) . Genetic Landscape and Emerging Therapies in Uveal Melanoma. Cancers, 13 (21), 5503. |[2]Gang Fu, et al., SMARCD1 is a dual regulator of PD-L1 expression and cell proliferation facilitating tumor evasion, Pathology - Research and Practice, Volume 270, 2025, 155975, ISSN 0344-0338. |[3]Reichl, K. D., et al., Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 2023. Expert Opinion on Therapeutic Patents, 34 (3), 159–169.|[4]Centore, R.C. et al. (2023) Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported